WO2000009102A3 - Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders - Google Patents

Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders Download PDF

Info

Publication number
WO2000009102A3
WO2000009102A3 PCT/US1999/018230 US9918230W WO0009102A3 WO 2000009102 A3 WO2000009102 A3 WO 2000009102A3 US 9918230 W US9918230 W US 9918230W WO 0009102 A3 WO0009102 A3 WO 0009102A3
Authority
WO
WIPO (PCT)
Prior art keywords
vision
carboxylic acids
isosteres
heterocyclic compounds
memory disorders
Prior art date
Application number
PCT/US1999/018230
Other languages
French (fr)
Other versions
WO2000009102A2 (en
WO2000009102A9 (en
Inventor
Douglas T Ross
Hansjorg Sauer
Gregory S Hamilton
Joseph P Steiner
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Priority to JP2000564605A priority Critical patent/JP2002522478A/en
Priority to AU54774/99A priority patent/AU5477499A/en
Priority to CA002340419A priority patent/CA2340419A1/en
Priority to MXPA01001646A priority patent/MXPA01001646A/en
Priority to EP99941050A priority patent/EP1105128A2/en
Publication of WO2000009102A2 publication Critical patent/WO2000009102A2/en
Publication of WO2000009102A3 publication Critical patent/WO2000009102A3/en
Publication of WO2000009102A9 publication Critical patent/WO2000009102A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

This invention relates to novel compositions and uses of N-heterocyclic carboxylic acids and carboxylic acid isosteres which have affinity for an FKBP-type (FKBP12) immunophilin and which inhibit its rotamase activity. These compounds can be immunosuppressive or non immunosuppressive for treating a vision disorder, improving vision, treating memory impairment or enhancing memory performance in an animal.
PCT/US1999/018230 1998-08-14 1999-08-12 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders WO2000009102A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000564605A JP2002522478A (en) 1998-08-14 1999-08-12 Carboxylic acids and isosteres of N-heterocyclic compounds for visual and memory impairment
AU54774/99A AU5477499A (en) 1998-08-14 1999-08-12 Carboxylic acids and isosteres of N-heterocyclic compounds for vision and memory disorders
CA002340419A CA2340419A1 (en) 1998-08-14 1999-08-12 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders
MXPA01001646A MXPA01001646A (en) 1998-08-14 1999-08-12 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders.
EP99941050A EP1105128A2 (en) 1998-08-14 1999-08-12 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/134,472 1998-08-14
US09/134,472 US7265150B1 (en) 1998-08-14 1998-08-14 Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders

Publications (3)

Publication Number Publication Date
WO2000009102A2 WO2000009102A2 (en) 2000-02-24
WO2000009102A3 true WO2000009102A3 (en) 2000-07-06
WO2000009102A9 WO2000009102A9 (en) 2000-08-03

Family

ID=22463546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018230 WO2000009102A2 (en) 1998-08-14 1999-08-12 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders

Country Status (7)

Country Link
US (1) US7265150B1 (en)
EP (1) EP1105128A2 (en)
JP (1) JP2002522478A (en)
AU (1) AU5477499A (en)
CA (1) CA2340419A1 (en)
MX (1) MXPA01001646A (en)
WO (1) WO2000009102A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4708567B2 (en) * 1998-12-03 2011-06-22 ジーピーアイ ニル ホールディングス インコーポレイテッド Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
DE102008060549A1 (en) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Drug-peptide construct for extracellular accumulation
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
PE20151521A1 (en) 2012-12-20 2015-11-25 Inception 2 Inc TRIAZOLONE COMPOUNDS AND USES OF THEM
WO2014201405A1 (en) 2013-06-14 2014-12-18 The Board Of Regents Of The University Of Texas System Novel allosteric inhibitors of proteasome and methods of use thereof
WO2015035059A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
US20170266157A1 (en) * 2016-03-21 2017-09-21 David Weinstein Methods for wound healing and scar prevention
WO2018195263A1 (en) 2017-04-20 2018-10-25 The Board Of Regents Of The University Of Texas System Methods for the treatment of cancer metastasis
CA3127990A1 (en) 2018-01-30 2019-08-08 Board Of Regents, The University Of Texas System Pipecolic esters for inhibition of the proteasome

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356399A2 (en) * 1988-08-26 1990-02-28 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0402931A1 (en) * 1989-06-14 1990-12-19 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
WO1992000278A1 (en) * 1990-07-02 1992-01-09 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
EP0484936A1 (en) * 1990-11-08 1992-05-13 Fujisawa Pharmaceutical Co., Ltd. Suspensions containing tricyclic compounds
DE4039587A1 (en) * 1990-12-12 1992-06-17 Sandoz Ag New derivs. of FR 520 and FK 506 - for treating transplant resistance, auto:immune diseases and inflammatory or hyper proliferative skin diseases
EP0509753A1 (en) * 1991-04-18 1992-10-21 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
WO1992019278A1 (en) * 1991-04-26 1992-11-12 Kurume University Use of macrolide compounds for eye diseases
WO1992021313A2 (en) * 1991-05-24 1992-12-10 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
WO1996040140A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Inhibitors of rotamase enzyme activity
WO1997016190A1 (en) * 1995-10-31 1997-05-09 Guilford Pharmaceuticals Inc. Rotamase enzyme activity inhibitors
WO1997025977A1 (en) * 1996-01-19 1997-07-24 Novartis Ag Pharmaceutical compositions
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
WO1998013343A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic thioesters and ketones
WO1998029116A1 (en) * 1996-12-31 1998-07-09 Guilford Pharmaceuticals Inc. N-linked sulfonamides of heterocyclic thioesters
WO1998041205A1 (en) * 1997-03-18 1998-09-24 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
WO1999042104A1 (en) * 1998-02-23 1999-08-26 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
WO1999045006A1 (en) * 1998-03-02 1999-09-10 Pfizer Inc. Heterocyclic compounds as inhibitors of rotamase enzymes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5244902A (en) 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5667968A (en) 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US5252319A (en) 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5457111A (en) 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5198454A (en) 1991-12-03 1993-03-30 Texas A&M University System Use of OB-104 to treat ocular inflammation
US5194434A (en) 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
ES2139005T3 (en) 1992-04-21 2000-02-01 Schepens Eye Res Inst EYE THERAPY WITH ANDROGEN IN SJOGREN'S SYNDROME.
CA2106034A1 (en) 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5693645A (en) 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5468752A (en) 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1998027975A1 (en) 1996-12-20 1998-07-02 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
US5935989A (en) * 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356399A2 (en) * 1988-08-26 1990-02-28 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0402931A1 (en) * 1989-06-14 1990-12-19 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
WO1992000278A1 (en) * 1990-07-02 1992-01-09 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
EP0484936A1 (en) * 1990-11-08 1992-05-13 Fujisawa Pharmaceutical Co., Ltd. Suspensions containing tricyclic compounds
DE4039587A1 (en) * 1990-12-12 1992-06-17 Sandoz Ag New derivs. of FR 520 and FK 506 - for treating transplant resistance, auto:immune diseases and inflammatory or hyper proliferative skin diseases
EP0509753A1 (en) * 1991-04-18 1992-10-21 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
WO1992019278A1 (en) * 1991-04-26 1992-11-12 Kurume University Use of macrolide compounds for eye diseases
WO1992021313A2 (en) * 1991-05-24 1992-12-10 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
WO1996040140A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Inhibitors of rotamase enzyme activity
WO1997016190A1 (en) * 1995-10-31 1997-05-09 Guilford Pharmaceuticals Inc. Rotamase enzyme activity inhibitors
WO1997025977A1 (en) * 1996-01-19 1997-07-24 Novartis Ag Pharmaceutical compositions
WO1998013343A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic thioesters and ketones
WO1998029116A1 (en) * 1996-12-31 1998-07-09 Guilford Pharmaceuticals Inc. N-linked sulfonamides of heterocyclic thioesters
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
WO1998041205A1 (en) * 1997-03-18 1998-09-24 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
WO1999042104A1 (en) * 1998-02-23 1999-08-26 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
WO1999045006A1 (en) * 1998-03-02 1999-09-10 Pfizer Inc. Heterocyclic compounds as inhibitors of rotamase enzymes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAMILTON ET AL.: "Neuroimmunophilin ligands as novel therapeutics for the treatment of degenerative disorders of the nervous system", CURR. PHARM. DESIGN, vol. 3, no. 4, 1997, pages 405 - 428, XP002125243 *
KAWASHIMA ET AL.: "Effects of a new immunospuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats", INVEST. OPHTHALMOL. VIS. SCI., vol. 29, 1988, pages 1265 - 1271, XP000856700 *
RAO ET AL.: "Treatment of uveitis with immunosuppressive agents", INDIAN J. OPHTHALMOLOGY, vol. 41, no. 3, 1993, pages 107 - 113, XP002125241 *
ROSS ET AL.: "The FKBP neuroimmunophilin lignand GPI-1046 enhances retinal ganglion cell survival and arrests axonal dying back following optic nerve transection", SOC. NEUROSCI. ABSTR., vol. 24, no. 1-2, 17 August 1998 (1998-08-17), pages 814, XP000856019 *
STEINER ET AL.: "Neurotrophic actions of non-immunosuppressive analogs of immunosuppressive drugs FK506, rapamycin and cyclosporin A", NAT. MED., vol. 3, no. 4, 1997, pages 421 - 428, XP002125244 *
STEINER ET AL.: "Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models", PROC. NATL ACAD. SCI., vol. 94, no. 5, 1997, pages 2019 - 2024, XP002125433 *
VALENTINE ET AL.: "Neuroimmunophilin ligands promote recovery from the peripheral sensory neuropathy associated with streptozocin-induced diabetes", SOC. NEUROSCI. ABSTR., vol. 24, no. 1-2, 17 August 1998 (1998-08-17), pages 481, XP000853536 *

Also Published As

Publication number Publication date
WO2000009102A2 (en) 2000-02-24
WO2000009102A9 (en) 2000-08-03
CA2340419A1 (en) 2000-02-24
MXPA01001646A (en) 2002-06-04
JP2002522478A (en) 2002-07-23
AU5477499A (en) 2000-03-06
US7265150B1 (en) 2007-09-04
EP1105128A2 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
WO2000009109A3 (en) Pipecolic acid derivatives for vision and memory disorders
CA2206799A1 (en) Small molecule inhibitors of rotamase enzyme activity
CA2206824A1 (en) Inhibitors of rotamase enzyme activity
CA2263927A1 (en) Heterocyclic thioesters and ketones
WO2000009102A3 (en) Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders
MXPA99006120A (en) N-linked sulfonamides of heterocyclic thioesters.
DE69629392D1 (en) INHIBITORS OF THE ACTIVITY OF CYCLOPHILIN ROTAMASE
CA2367017A1 (en) Inhibitors of impdh enzyme
EP0843995A3 (en) Use of substituted benzazoles as UV absorbents, new benzazoles and their preparation
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
ZA200705752B (en) 7- {4-[2-(2,6-Dichloro-4-methylphenoxy)-ethoxy] phenyl}-3,9-diazabicyclo [3.3.1] non-6-ene-6-carboxylic acid cyclopropyl- (2,3-dimethylbenzyl) amides as inhibitors of renin for the treatment of hypertension
NO981903L (en) Small-molecule inhibitors of rotamase enzyme activity
WO2001023389A3 (en) Certain alkylene diamine-substituted heterocycles
WO2000009107A3 (en) Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
AP9901479A0 (en) Heterocyclic compounds as inhibitors of rotamase enzymes.
WO2000006085A3 (en) Compounds and methods
TW200508385A (en) Cleaning agent for removing solder flux and method for cleaning solder flux
WO2005110469A3 (en) Methods and compositions for reducing oxalate concentrations
WO2002030357A3 (en) Compounds and methods for modulating ccr4 function
WO2000009103A3 (en) N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders
WO2000009112A3 (en) Heterocyclic esters or amides for vision and memory disorders
WO2003046135A3 (en) Osteopontin-related compositions and methods
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2007024752A3 (en) Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
WO2000050631A3 (en) Compositions and methods for monitoring the modification of natural binding partners

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-102, DESCRIPTION, REPLACED BY NEW PAGES 1-68; PAGES 103-112, CLAIMS, REPLACED BY NEW PAGES 69-76; PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 54774/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2340419

Country of ref document: CA

Ref country code: CA

Ref document number: 2340419

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001646

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999941050

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999941050

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999941050

Country of ref document: EP